Health committee  I think in Canada it's not just about having the best health care, but it's about having the best health care equitably delivered. It has to be equitable within provinces as much as possible, and between provinces as well. In terms of drug approval, Health Canada controls that process.

Health committee  I think Marco was waving goodbye, and I can't stay for more questions.

Health committee  I can do another five minutes as well.

Health committee  I think that researchers tend to be very imaginative and carrots tend to work very well. You do control funding. If you decide that removing red tape is a valuable thing to do, you can work on it inside Ottawa, but also you could present funding opportunities that have to be interprovincial and address major issues surrounding the personalization of health care.

Health committee  Ten minutes or so more. The fact is he'd be late for the next meeting.

Health committee  This does come back, I think, to some point that Marco and I made, and others alluded to. If we are going to embrace the concept of more individualized disease control as a way of improving the effectiveness, cost-effectiveness, and appeal of our health care system, we have to refit our drug approval processes and the way we consider new interventions so that they're tailored for personalized interventions, as opposed to what we've had in the past.

Health committee  Thank you for the honour of speaking with you today. As Marco indicated, I work very closely with Marco and I, like many of you, wear several hats. I run our ovarian cancer research team and we've managed to make huge progress in British Columbia in the understanding of this disease by having access to the infrastructure, which Marco and his colleagues have built.